AlM:To compare the efficacy and complication of extra-trabeculotomy in combination with trabeculectomy and trabeculectomy and compound trabeculectomy in the treatment of primary infantile glaucoma.
METHODS: Patients with primary infantile glaucoma undergone one of the three procedures from Jan 2006 to Jan 2014 were selected. Among them, group A ( 20 patients, 31 eyes ) underwent extra- trabeculotomy in combination with trabeculectomy, group B ( 20 patients, 32 eyes ) underwent trabeculectomy, while group C ( 20 patients, 30 eyes) underwent compound trabeculectomyRESULTS:The success rates in group A were 96. 8% at the time of discharge and 90. 3% during follow-up (mean 24mo) ; the rates in group B were 96. 9% and 81. 2%( mean 24mo) the rates in group C were 83. 3% and 76. 7%( mean 24mo ) respectively, the differences being significant (P <0. 05). ln group A and group B, there was no severe complications, while in group C, one case had vitreous prolapse.
CONCLUSlON: Extra - trabeculotomy in combination with trabeculectomy is more efficacious and safer than trabeculectomy and compound trabeculectomy in the treatment of primary infantile glaucoma. lt should be the first choice for primary infantile glaucoma.

Child ; Evidence-Based Medicine ; Guidelines as Topic ; Humans ; Urinary Tract Infections ; diagnosis ; therapy

Child ; Humans ; Liver Diseases ; Mitochondrial Diseases

Adolescent ; Adult ; Aged ; Diagnosis, Differential ; Ependymoma ; pathology ; Female ; Follow-Up Studies ; Humans ; Immunohistochemistry ; Magnetic Resonance Imaging ; Male ; Meningeal Neoplasms ; diagnostic imaging ; metabolism ; pathology ; surgery ; Meningioma ; diagnostic imaging ; metabolism ; pathology ; surgery ; Mucin-1 ; metabolism ; Oligodendroglioma ; pathology ; Tomography, X-Ray Computed ; Vimentin ; metabolism ; Young Adult

Abstract Objective: To study the relationshiop between the HBV pre-c mutant and the clinical the, the host immunity. Methods: Mu-tation specific PCR(msPCR) was employed for detecting pre-c mutant in 92 cases with HBV-DNA positive;T subpopulations were determinedby APAAP immune-bridge assay; the cytokines (TNF?、 sIL-2R ) levels by ELISA. Results: 57 cases had Pre-c mutant, the rate was ahaut 62 %;pre-c mutant existed popularly in different e systems status, mainly in anti-HBe(+) serum. The reat increased with the deterioration of liverfunction, and was highest in fulminant hepatitis, the percentage of CD4 T lymphocyte and the ratio of CD4/CD8 were aignificantly lower in mu-tational group than in wild group,but CD8 T lymphocyte was obviously higher, the quantity of sera TNF? and sIL-2R in mutational group wereobviously higher than in wild group, both groups were obviously higher than control group. Conclusion:PreC 1896 mutant existed popularly inpatients with HBV infection. There were more serious disturbance in host immunity in mutant group. The mutant may be associated with the pre-ssare of host immune system.The mutant type virus could provoke host immunity resulting in severe liver damage.

This paper discussed AIDS epidemic sityation and it's tendency, AIDS harmful-ness to human beings health and social economic development. The dangerous factors of AIDS epidemic in china is pointed out. prsvent and treatment AIDS is urgency.

OBJECTIVE: To evaluate the uncertainty of pH measurement in pharmaceuticals. METHODS: Taking glucose and sodium chloride injection as an example, the uncertainty of pH measurement in pharmaceuticals was evaluate by uncertainty transmission rule's method (GUM) and Monte Carlo method (MCM), and the uncertainties obtained by the two methods were compared. RESULTS: The measurement uncertainty obtained by GUM almost agreed with that by MCM. CONCLUSION: MCM is easy and reliable, and can be used as an alternative method for evaluation of the measurement uncertainty in pharmaceutical analysis.

The main significant change of the Chinese Pharmacopoeia (Ch. P) 2015 edition is the development of volume IV for the first time based on integrating the appendices of the Ch. P volume I (traditional Chinese drug), II (chemical drugs) and III (biologics), including the general requirements for preparations, testing methods, guidelines as well as the excipients standards. The Ch. P 2015 volume IV, as the general requirements, is the most important part of Ch. P. The Ch. P 2015 volume IV has made a great progress in improving testing methods, application of advanced analysis technology, strengthening process quality control, improving the control system for excipients as well as establishing the excipients monographs. It will play an important role in improving the overall standards of Ch. P, strengthening the drug quality control and assuring the drug quality.